Table 2.
Comparison of clinical characteristics between thrombocytopenia and no thrombocytopenia
| Variables | Platelet count < 100 × 109/La | The drop decrease of platelet count was ≥ 25%b | ||||
|---|---|---|---|---|---|---|
| No thrombocytopenia | Thrombocytopeniaa | p | No thrombocytopenia | Thrombocytopeniaa | p | |
| Total, n (%) | 247 (77.2%) | 73 (22.8%) | 184 (57.5%) | 136 (42.5%) | ||
| Sex, n (%) | 0.302 | 0.214 | ||||
| Male | 167 (75.6%) | 54 (24.4%) | 122 (55.2%) | 99 (44.8%) | ||
| Female | 80 (80.8%) | 19 (19.2%) | 62 (62.6%) | 37 (37.4%) | ||
| Age (years) | 68.47 ± 16.12 | 73.78 ± 16.77 | 0.015 | 67.93 ± 16.15 | 72.05 ± 16.48 | 0.026 |
| Hospitalization days | 24.19 ± 15.29 | 25.84 ± 16.57 | 0.429 | 22.82 ± 14.00 | 26.93 ± 17.26 | 0.024 |
| Total bilirubin level | 18.18 ± 39.06 | 27.53 ± 75.58 | 0.312 | 20.03 ± 44.94 | 20.69 ± 55.91 | 0.908 |
| ALT | 61.69 ± 154.05 | 115.84 ± 222.65 | 0.055 | 70.92 ± 175.82 | 78.26 ± 170.21 | 0.709 |
| AST | 70.35 ± 207.09 | 136.19 ± 244.14 | 0.039 | 81.45 ± 238.08 | 90.68 ± 186.70 | 0.708 |
| Total protein (g/L) | 59.51 ± 9.41 | 59.64 ± 10.53 | 0.923 | 59.39 ± 9.66 | 59.75 ± 9.69 | 0.740 |
| Serum albumin (g/L) | 31.89 ± 5.51 | 30.77 ± 5.23 | 0.125 | 32.13 ± 5.40 | 30.96 ± 5.48 | 0.059 |
| Haemoglobin (g/L) | 108.03 ± 23.00 | 110.95 ± 27.72 | 0.366 | 108.48 ± 23.80 | 109.00 ± 24.69 | 0.848 |
| Platelet count (109/L) | 236.45. ± 118.15 | 162.12 ± 81.53 | 0.000 | 214.66 ± 113.35 | 225.88 ± 117.42 | 0.390 |
| Creatinine clearance, mL/min | 0.005 | 0.113 | ||||
| ≥ 60 | 159 (82.4%) | 34 (17.6%) | 120 (62.2%) | 73 (37.8%) | ||
| ≥ 30, < 60 | 56 (74.7%) | 19 (25.3%) | 38 (50.7%) | 37 (49.3%) | ||
| < 30 | 32 (61.5%) | 20 (38.5%) | 26 (50.0%) | 26 (50.0%) | ||
| Intensive care, n (%) | 0.327 | 0.205 | ||||
| No intensive care | 121 (79.6%) | 31 (20.4%) | 93 (61.2%) | 59 (38.8%) | ||
| Intensive care | 126 (75.0%) | 42 (25.0%) | 91 (54.2%) | 77 (45.8%) | ||
| Shockc, n (%) | 0.007 | 0.012 | ||||
| No shock | 174 (81.7%) | 39 (18.3%) | 133 (62.4%) | 80 (37.6%) | ||
| Shock | 73 (68.2%) | 34 (31.8%) | 51 (47.7%) | 56 (52.3%) | ||
| Linezolid therapy duration days, mean ± SD | 6.93 ± 5.47 | 9.01 ± 6.41 | 0.006 | 6.93 ± 5.47 | 9.01 ± 6.41 | 0.006 |
| Linezolid therapy duration, days, | 0.002 | 0.000 | ||||
| < 7d | 145 (84.8%) | 26 (15.2%) | 121 (70.7%) | 50 (29.3%) | ||
| ≥ 7, < 14d | 74 (67.9%) | 35 (32.1%) | 45 (41.3%) | 64 (58.7%) | ||
| ≥ 14d | 28 (70.0%) | 12 (30.0%) | 18 (45.0%) | 22 (55.0%) | ||
| Comorbid diseases, n (%) | ||||||
| Malignant tumor | 15 (78.9%) | 4 (21.1%) | 0.850 | 12 (63.2%) | 7 (36.8%) | 0.607 |
| Hypertension | 135 (77.6%) | 39 (22.4%) | 0.853 | 102 (58.6%) | 72 (41.4%) | 0.658 |
| Cardiac insufficiency | 65 (67.0%) | 32 (33.0%) | 0.004 | 48 (49.5%) | 49 (50.5%) | 0.056 |
| Diabetes | 58 (77.3%) | 17 (22.7%) | 0.973 | 48 (64.0%) | 27 (36.0%) | 0.193 |
| Stroke | 77 (82.8%) | 16 (17.2%) | 0.126 | 58 (62.4%) | 35 (37.6%) | 0.260 |
| Chronic lung disease | 18 (72.0%) | 7 (28.0%) | 0.520 | 15 (60.0%) | 10 (40.0%) | 0.792 |
| Concurrent medications | ||||||
| Aspirin | 24 (53.3%) | 21 (46.7%) | 0.542 | 23 (51.1%) | 22 (48.9%) | 0.541 |
| Clopidogrel | 32 (84.2%) | 6 (15.8%) | 0.272 | 26 (68.4%) | 12 (31.6%) | 0.147 |
| Low molecular weight heparin | 56 (70.9%) | 23 (29.1%) | 0.124 | 42 (53.2%) | 37 (46.8%) | 0.369 |
ALT Alanine aminotransferase, AST Glutamic oxaloacetic transaminase
Bold values show statistical significance of differences
aThrombocytopenia with platelet count < 100 × 109/L and a decrease in 25% or more from baseline of the platelet count
bThrombocytopenia due to a platelet count drop decrease of 25% or more from baseline
cShock patients require vasoactive medications